Trafalgar International (GCAN) Accumulated Expenses (2016 - 2026)
Trafalgar International (GCAN) posted Accumulated Expenses of $500350.0 for Q1 2026, up 6.38% on a QoQ basis from $470350.0 in Q4 2025, and up 21.93% year-over-year from $410350.0 in Q1 2025.
Analysis
Trafalgar International (GCAN) Accumulated Expenses (2016 - 2026) Analysis & Trends
Trafalgar International has reported Accumulated Expenses for 11 years, with the latest figure at $500350.0 in Q1 2026.
- On a quarterly basis, Accumulated Expenses rose 21.93% year-over-year to $500350.0 in Q1 2026; TTM through Mar 2026 was $500350.0, a 21.93% increase from a year earlier, with the FY2025 full-year figure at $470350.0, up 23.66% from the prior year.
- Accumulated Expenses was $500350.0 for Q1 2026 at Trafalgar International, up from $470350.0 in the prior quarter.
- The five-year high for Accumulated Expenses was $500350.0 in Q1 2026, with the low at $60000.0 in Q2 2025.
- Average Accumulated Expenses over 5 years is $339653.6, with a median of $340350.0 recorded in 2023.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses soared 28524.08% in 2022, then tumbled 81.84% in 2025.
- Over 5 years, Accumulated Expenses stood at $263000.0 in 2022, then climbed by 29.41% to $340350.0 in 2023, then gained by 11.75% to $380350.0 in 2024, then climbed by 23.66% to $470350.0 in 2025, then gained by 6.38% to $500350.0 in 2026.
- The last three Accumulated Expenses figures came in at $500350.0 (Q1 2026), $470350.0 (Q4 2025), and $460350.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 500,350.00 |
| Dec 31, 2025 | 470,350.00 |
| Sep 30, 2025 | 460,350.00 |
| Jun 30, 2025 | 60,000.00 |
| Mar 31, 2025 | 410,350.00 |
| Dec 31, 2024 | 380,350.00 |
| Sep 30, 2024 | 350,350.00 |
| Jun 30, 2024 | 330,350.00 |
| Mar 31, 2024 | 340,350.00 |
| Dec 31, 2023 | 340,350.00 |
| Jun 30, 2023 | 323,000.00 |
| Mar 31, 2023 | 293,000.00 |
| Dec 31, 2022 | 263,000.00 |
| Mar 31, 2022 | 233,000.00 |
| Dec 31, 2021 | 203,000.00 |
| Sep 30, 2021 | 203,000.00 |
| Jun 30, 2021 | 10,613.00 |
| Mar 31, 2021 | 814.00 |
| Dec 31, 2020 | 152,000.00 |
| Sep 30, 2020 | 18,462.00 |